APRE – aprea therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Aprea Therapeutics (NASDAQ:APRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at HC Wainwright from $20.00 to $5.00. They now have a "buy" rating on the stock.
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update [Yahoo! Finance]
Form 8-K Aprea Therapeutics, Inc. For: Jan 09
Form EFFECT Aprea Therapeutics, Inc.
Form 424B3 Aprea Therapeutics, Inc.
Form D Aprea Therapeutics, Inc.
Form S-3 Aprea Therapeutics, Inc.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.